Abstract
Background and Aims The reported case numbers of COVID-19 are often used to estimate the reproduction number or the growth rate. We use the excess mortality instead, showing the difference between most restrictive non-pharmaceutical interventions (mrNPIs) and less restrictive NPIs (lrNPIs) with respect to the growth rate and death counts.
Methods We estimate the COVID-19 growth rate for Sweden, South Korea, Italy and Germany from the excess mortality. We use the average growth rate obtained for Sweden and South Korea, two countries with lrNPIs, to estimate additional death numbers in Germany and Italy (two countries with mrNPIs) in a hypothetic lrNPIs scenario.
Results The growth rate estimated from excess mortality decreased faster for Germany and Italy than for Sweden and South Korea, suggesting that the mrNPIs have a non-negligible effect. This is not visible when the growth rate is calculated using the reported case numbers of COVID-19. This results in approximately 4 500 and 12 000 more death numbers for Germany and Italy, respectively.
Conclusion The reproduction numbers or growth rates obtained from reported COVID-19 cases are most likely biased. Expanding testing capacity led to an overestimation of the growth rate across all countries analyzed, masking the true decrease already visible in the excess mortality. Using our method, a more realistic estimate of the growth rate is obtained. Conclusions made for the reproduction number derived from the reported case numbers like the insignificance of most restrictive non-pharmaceutical interventions (lockdowns) might be wrong and have to be reevaluated using the growth rates obtained with our method.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
NA since no funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NA since independent researcher
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
1
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos